Stockscreener 앱 받기
0.378
0.27%
0.001
Turnstone Biologics Corp 주식(TSBX)의 최신 뉴스
Q1 EPS Forecast for Turnstone Biologics Decreased by Analyst - Defense World
Analysts Set Expectations for TSBX Q1 Earnings - Defense World
Turnstone Biologics Corp: Strategic Partnerships and Financial Position Justify Hold Rating - TipRanks
Turnstone Biologics Reports 2024 Financial Results - TipRanks
Turnstone Biologics moves to Nasdaq Capital Market By Investing.com - Investing.com South Africa
Turnstone Biologics moves to Nasdaq Capital Market - Investing.com
Turnstone Biologics Corp. SEC 10-K Report - TradingView
Turnstone Biologics Cuts Losses by $3.6M as Company Pivots Strategy - Stock Titan
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Significant Growth in Short Interest - Defense World
Turnstone Biologics (TSBX) Expected to Announce Earnings on Thursday - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.35 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.35 - Investing.com India
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering, Business Wires News - AsiaOne
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Large Drop in Short Interest - Defense World
Turnstone Biologics Stock Hits 52-Week Low at $0.36 Amid Challenges - Investing.com Australia
Turnstone Biologics halts TIDAL-01 development, seeks alternatives - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 By Investing.com - Investing.com Canada
Cautious Hold on Turnstone Biologics Amid TIL Therapy Challenges and Strategic Alternatives - TipRanks
Analysts Offer Predictions for TSBX FY2024 Earnings - Defense World
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Leerink Partnrs Weighs in on TSBX FY2024 Earnings - Armenian Reporter
Turnstone Biologics (NASDAQ:TSBX) Stock Rating Lowered by Piper Sandler - Defense World
A Look at Turnstone Biologics Corp (TSBX) Shares in the Recent Past Indicates Growth - SETE News
TSBX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Turnstone Biologics to explore strategic alternatives - The Pharma Letter
Piper Sandler Downgrades Turnstone Biologics to Neutral From Overweight, Adjusts Price Target to $0.40 From $3.75 - Marketscreener.com
Turnstone Biologics Corp (NASDAQ: TSBX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Piper Sandler cuts Turnstone Biologics stock rating to neutral - MSN
Turnstone Biologics halts TIDAL-01 development, seeks alternatives By Investing.com - Investing.com South Africa
Ottawa-born Turnstone Biologics halting clinical studies, laying off staff - Ottawa Business Journal
TSBX’s price-to-book ratio: An indicator of the company’s performance - US Post News
Turnstone Biologics Stops Tidal-01 Trials, Explores Strategic Alternatives; Shares Rise - Marketscreener.com
Turnstone Biologics Halts TIDAL-01 Studies Amid Market Woes - TipRanks
Turnstone Biologics Announces Plans to Explore Strategic Alternatives - The Manila Times
Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review - Nasdaq
Scailyte Announces Collaboration With Turnstone Biologics to Identify Biomarker Signatures in Solid Tumors With TIL Therapy - ACCESS Newswire
Head to Head Survey: Turnstone Biologics (NASDAQ:TSBX) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Reviewing AlloVir (NASDAQ:ALVR) and Turnstone Biologics (NASDAQ:TSBX) - Defense World
Turnstone Biologics (NASDAQ:TSBX) Stock Price Down 9.1% – Time to Sell? - Defense World
Fmr LLC Boosts Stock Position in Turnstone Biologics Corp. (NASDAQ:TSBX) - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.44 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.44 - Investing.com
2.65%
0.06%
자본화:
|
볼륨(24시간):